BACKGROUND: The glycoprotein (GP) IIb/IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is approved for use in high-risk percutaneous transluminal coronary angioplasty (PTCA). At present, no "point of care" exists for measuring pharmacological @entity1427 /IIIa blockade. To address this need, the Chrono-log Whole Blood Aggregometer, which measures @entity1423 by electrical impedance, was adapted to test platelet function at the bedside. METHODS AND RESULTS: @entity1427 /IIIa receptor blockade, impedance (5 microg/mL collagen), and @entity1423 (5 and 20 micromol/L @entity857 ) measurements were obtained on 14 PTCA @entity1 who received the standard bolus plus a 12-hour infusion of abciximab. During abciximab administration, mean @entity1427 /IIIa receptor blockade was > 91%, and both impedance and @entity1423 were inhibited by > or = 90%. At 12 hours after abciximab treatment, the mean inhibition of turbidimetric @entity1423 to 5 and 20 micromol/L @entity857 was 65+/-20% and 49+/-14%, respectively, and inhibition of impedance aggregation was 69+/-12%. @entity1427 /IIIa receptor blockade was 67+/-8%. At 36 hours after abciximab treatment (n=8), the mean inhibition of turbidimetric @entity1423 to 5 and 20 micromol/L @entity857 was 44+/-21% and 30+/-14%, respectively, whereas impedance aggregation was inhibited by 60+/-14%. @entity1427 /IIIa receptor blockade was 57+/-7%. CONCLUSIONS: During and at 12 hours after abciximab therapy, impedance and turbidimetric @entity1423 to 5 micromol/L @entity857 were comparable and closely correlated with @entity1427 /IIIa receptor blockade. However, at 36 hours after abciximab treatment, impedance @entity1423 more closely paralleled @entity1427 /IIIa receptor blockade and indicated a slower recovery of platelet function than turbidimetric aggregometry.

Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti- XXXX /IIIa therapy.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity857 :: ('MESH:D000244', 'Chemical') :: ['ADP'] @entity1427 :: ('3674', 'Gene') :: ['GP IIb'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation', 'turbidimetric aggregation']
@entity1427 :: (3674,Gene) :: ['GP IIb']
